(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company
developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the thirteenth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland (“LDOS002”).
- 0 Comments
- FY2015